By Aaru Life Science | April 2026
For the past two decades, if you needed bulk chemicals, specialty chemicals, or pharmaceutical intermediates, the answer was often the same: source from China. It was cheaper. It was available in large quantities. And for a long time, it worked well enough.
That model is now under serious pressure from multiple directions simultaneously. And the gap it’s creating is one that Indian chemical suppliers are positioned to fill, if they move with the right focus and speed.
What’s Actually Happening in China Right Now
China’s chemical industry is dealing with a combination of problems that have compounded over the past two years.
Overcapacity and margin collapse. Global petrochemical operating rates have fallen to approximately 70%, considerably below pre-COVID averages of around 80% (McKinsey, March 2026). Chinese producers who had aggressively expanded capacity during the demand boom are now running plants well below optimal rates, squeezing margins to breakeven or below.
Slowing production growth. China’s chemical production growth is forecast to slow to just 1.3% in 2026, down sharply from prior years. The housing and construction slowdown has cut domestic demand. Export markets are facing US tariffs, which have made Chinese chemical exports to America significantly more expensive.
The “anti-involution” shift. In April 2026, Emkay Research published findings from an extensive on-ground assessment of Chinese manufacturing hubs. Their key conclusion: China is moving away from the era of “irrational pricing” where Chinese producers sold at or below breakeven simply to maintain market share. This shift toward more sustainable, value-driven pricing is called “anti-involution,” and it’s a structural change, not a temporary one. The era of abnormally cheap Chinese chemicals is ending.
Global Buyers Are Already Responding
The trade data from early 2025 is revealing. Through the first half of 2025, US imports of chemicals from China saw a steep decline, while shipments from India remained resilient and showed mild growth (Fibre2Fashion/Alchempro, November 2025).
It’s not only the US making this shift. Europe is watching its own chemical manufacturing base shrink at an alarming pace. In July 2025, Sabic closed its olefins cracker in Teesside, UK. Dow announced it would shut its ethylene cracker in Böhlen, Germany, citing structural challenges. ExxonMobil confirmed the closure of its Fife Ethylene Plant in Scotland in February 2026 (Chemistry World, December 2025).
When European plants close, the region’s self-sufficiency in basic chemicals drops. That demand has to be sourced from somewhere. India is one of the most logical places to look.
Meanwhile, global buyers building “China+1” sourcing strategies where they maintain Chinese supply but actively develop an alternative source are increasingly landing on India as their primary option. Low labor costs, a skilled workforce, a large domestic chemical industry, and geographic proximity to the Middle East (a key feedstock source) all work in India’s favor (C&EN, February 2026).
India’s Chemical Industry: Where It Actually Stands
India’s chemical industry was valued at approximately USD 155–165 billion in 2025 and is projected to grow at 8–9% CAGR over the next five to six years, reaching USD 230–255 billion (McKinsey, March 2026). Long-term projections put it at USD 1 trillion by 2040 (McKinsey/Oliver Wyman).
That’s not just domestic growth. India’s export trajectory has been impressive. In FY26 (April–July 2025 alone), exports of organic chemicals stood at USD 2,750.32 million, while dye and dye intermediate exports totaled USD 824.77 million (IBEF, 2025).
The government is backing this with serious capital. FDI inflows into India’s chemicals sector (excluding fertilizers) topped Rs. 1,42,647 crore (USD 23.2 billion) by FY25. The Union Budget 2025–26 allocated Rs. 1,61,965 crore (USD 18.7 billion) to the Ministry of Chemicals and Fertilizers. The Production-Linked Incentive (PLI) scheme attracted USD 844 million in FDI in 2024 alone (IBEF/Statista).
Indian companies are also moving globally. In June 2025, Aditya Birla Group acquired Cargill’s specialty chemicals manufacturing facility in Dalton, Georgia, USA an outright strategic acquisition of a US asset, signaling that India’s ambitions extend well beyond being a low-cost exporter.
McKinsey analysis identifies eight key growth arenas including construction, semiconductors, renewables, and automotive that will add USD 30–35 billion to India’s chemical revenues by 2030 as downstream capacity expands through government funding and supply chain localization.
The Honest Challenges Because They’re Real
Any serious assessment has to include the difficulties. And there are several.
US tariffs are a headwind. The US imposed nearly 50% tariffs on Indian goods in 2025, which directly hurt export-oriented chemical companies. Industry advisor Ajay Joshi noted in February 2026 that the tariffs would continue making 2026 a tough year for Indian chemical exporters specifically (C&EN, February 2026).
Raw material dependency is a structural weakness. India’s approximately USD 31 billion chemical trade deficit in 2025 reflects significant dependence on imported raw materials particularly in inorganic chemicals and polymers (McKinsey/UN Comtrade, 2026). NITI Aayog’s 2025 report flagged this directly as a constraint on long-term competitiveness.
Chinese redirection is a risk too. As Chinese producers face US tariff barriers, some are redirecting their export volumes toward India and other Asian markets potentially increasing competition and depressing prices in domestic markets.
These are real challenges. They don’t erase the opportunity, but they do mean that success isn’t automatic.
Where the Real Opportunity Lies for Domestic-Focused Suppliers
Here’s the important distinction that often gets missed in these conversations: the tariff headwinds primarily hurt export-oriented Indian chemical companies those heavily reliant on the US market.
For domestic-focused suppliers serving Indian pharmaceutical manufacturers, oilfield operators, industrial users, and home care brands, the picture is different. Domestic demand in India remains healthy. The same supply chain diversification logic that is pushing global buyers toward India also applies to Indian companies buying chemicals for their own production they want reliable domestic sources, not dependence on Chinese imports that could be disrupted.
India’s approximately USD 31 billion trade deficit in chemicals means there is an enormous import substitution opportunity sitting right here at home. Every rupee of chemical import that a domestic supplier can replace is revenue captured from global competition.
For companies like Aaru Life Science supplying pharmaceutical-grade chemicals, oilfield chemicals, and specialty industrial chemicals to Indian buyers the question is not whether demand is growing. It is. The question is whether you have the quality consistency, technical capability, and reliability to become the preferred domestic source as buyers reduce their China exposure.
The Bottom Line
China’s chemical dominance isn’t disappearing overnight. But it is shrinking through a combination of overcapacity, slowing growth, structural pricing shifts, and deliberate diversification by global buyers.
India has the scale, the workforce, the policy support, and the geographic advantage to be the primary beneficiary of this shift. The companies that build their capabilities and relationships now will be positioned to capture a disproportionate share of what happens next.
The window is open. How long it stays open depends on how fast Indian suppliers move.
Aaru Life Science Green chemicals, biodegradable solutions, and sustainable alternatives for Indian industry.
